# Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances

> **NCT06349759** · PHASE3 · COMPLETED · sponsor: **Ocuphire Pharma, Inc.** · enrollment: 200 (actual)

## Conditions studied

- Mesopic Vision
- Night Vision Loss

## Interventions

- **DRUG:** phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06349759
- **Lead sponsor:** Ocuphire Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-01
- **Primary completion:** 2025-04-17
- **Final completion:** 2026-02-19
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2026-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06349759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06349759, "Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06349759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*